Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 10, 2022 16:05 ET
|
Oyster Point Pharma, Inc.
TYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3’22Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by...
Iridex Announces Record Third Quarter 2022 Financial Results
November 10, 2022 16:05 ET
|
IRIDEX Corporation
MOUNTAIN VIEW, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal...
MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc.
November 10, 2022 08:00 ET
|
MeiraGTx
-- Updated Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) -- Now Dosing Patients in Phase 1 Trial...
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
November 08, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following fourth...
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
November 07, 2022 08:00 ET
|
Oyster Point Pharma, Inc.
Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per SharePRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) --...
Axogen to Participate at Upcoming Investor Conferences
November 03, 2022 16:00 ET
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
RNA Based Therapeutics and Vaccines Market Report 2022-2032
November 03, 2022 13:42 ET
|
ReportLinker
New York, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "RNA Based Therapeutics and Vaccines Market Report 2022-2032" -...
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting
November 03, 2022 13:00 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
Hyaluronic Acid Market Size to Surpass USD 20144.59 Million by 2027 at 6.77% CAGR – Report by Market Research Future (MRFR)
November 03, 2022 12:30 ET
|
Market Research Future
New York, USA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Hyaluronic Acid Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Hyaluronic Acid Market Information...
Oculis Strengthens its Scientific Advisory Board with World-Leading Ophthalmology Experts to Support Pipeline Development
November 03, 2022 09:07 ET
|
Oculis
Oculis Strengthens its Scientific Advisory Board with World-Leading Ophthalmology Experts to Support Pipeline Development Appointments support Company pipeline with major programs and readouts...